ValuEngine upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a strong sell rating to a sell rating in a research report sent to investors on Wednesday morning.

A number of other research firms also recently issued reports on CHRS. Zacks Investment Research downgraded shares of Coherus Biosciences from a hold rating to a sell rating in a research note on Tuesday, October 10th. BidaskClub upgraded shares of Coherus Biosciences from a sell rating to a hold rating in a research note on Thursday, December 21st. Credit Suisse Group reiterated an outperform rating and set a $17.00 price objective (down from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. Maxim Group reiterated a buy rating and set a $20.00 price objective (down from $40.00) on shares of Coherus Biosciences in a research note on Friday, September 8th. Finally, Cowen reiterated an outperform rating and set a $45.00 price objective on shares of Coherus Biosciences in a research note on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $29.67.

Coherus Biosciences (CHRS) opened at $12.35 on Wednesday. The company has a market cap of $739.58, a P/E ratio of -2.28 and a beta of 3.89. Coherus Biosciences has a 1 year low of $8.05 and a 1 year high of $28.60. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. research analysts anticipate that Coherus Biosciences will post -4.39 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in Coherus Biosciences by 32.7% in the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,785 shares in the last quarter. Legal & General Group Plc boosted its stake in Coherus Biosciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 1,046 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Coherus Biosciences by 497.4% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 10,491 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Coherus Biosciences in the second quarter valued at approximately $185,000. Finally, Voya Investment Management LLC boosted its stake in Coherus Biosciences by 32.2% in the second quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after acquiring an additional 4,293 shares in the last quarter. Institutional investors own 81.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/coherus-biosciences-chrs-raised-to-sell-at-valuengine/1797251.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.